Posted by Michael Wonder on 03 Mar 2026
Alnylam receives positive recommendation from Canada's Drug Agency for the public reimbursement of Amvuttra (vutrisiran injection), the first and only RNAi therapeutic for the treatment of cardiomyopathy in adult patients with ATTR amyloidosis
2 March 2026 - Alnylam Canada is pleased to announce it has received a positive recommendation from Canada's Drug Agency for the public reimbursement of its RNAi therapeutic, Amvuttra.
In December 2025, Amvuttra was authorized by Health Canada for the treatment of cardiomyopathy in adult patients with wild type or hereditary transthyretin-mediated amyloidosis (wtATTR or hATTR amyloidosis).
This is an expanded indication for Amvuttra, which was originally authorised for sale in Canada in 2023 for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis.
